Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 252-029-5 | CAS number: 34443-12-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The absorption/excretion, toxicokinetics, metabolism and distribution data of TBEC were evaluated from the available toxicological data and the physicochemical properties as suggested by the REACH Guidance Chapter R.7c.
TBEC is a clear colorless liquid at room temperature with a molecular weight of 246.3 g/mol. The substance is only very slightly soluble in water (5.39 mg/L). The logKow of TBEC was measured to be 5.2. Based on this log Kow a logBCF of 3.1 was calculated. TBEC (without its impurities) has a very low vapor pressure of 4 10e-7 Pa at 20 °C.
Absorption
Oral
TBEC is at least partially degraded hydrolytically to 2-ethylhexanol at 25 °C, with half-live of 19.4, 83.0, 131.3 and 98.0 h at pH 9, 8, 7 and 4, respectively. Tert-butanol was not detected during the hydrolysis tests. The half-life of TBEC hydrolysis decreases when increasing the temperature at pH 9: t1/2 is 19.4 h at 25 °C, 4.7 h at 37 °C, and 1.4 h at 50 °C. In addition, hydrolysis occurs at pH 4 (rat stomach pH), with a half-life of 12.9 hours at 37°C. Regarding these data, it can be expected that hydrolysis at pH 1.2 (human stomach pH) and 37 °C is possible but relatively limited.
This means that following oral exposure, mainly TBEC (and not its possible hydrolysis by products) will be absorbed both in human and in rats.
Oral absorption is favored for molecular weights below 500 g/mol. Based on the high logKow of 5.2 and the water solubility, TBEC may be taken up by micellular solubilisation. When administered orally TBEC may hydrolyze to 2-ethylhexanol but in a relatively small extent. Acute and subacute oral toxicity of TBEC are low.
Using a model to predict either high or low fraction absorbed for an orally administered, passively transported substance, the rates of absorption of TBEC were 100 and 90% for doses of 1 and 1000 mg, respectively (Danish QSAR database). According to the pkCSM method (Pires et al., 2015) for predicting small-molecule pharmacokinetic properties, TBEC is also expected to be readily absorbed (91%) by the oral route. Therefore, for human risk assessment, a default absorption rate of 100% will be used.
Dermal
Based on physico–chemical properties of TBEC the substance is not likely to penetrate skin to a large extent as the high logKow value and the low water solubility do not favor dermal penetration.
The dermal absorption of TBEC was estimated with IH SkinPerm v2.04 model (AIHA, 2018). Compared to in vitro data from OECD 428 studies, IH skinPerm allowed the estimation of the dermal absorption rate with a good confidence and a low frequency (ca. 2%) of underestimation for liquids (Arkema’s internal validation study, 2018). According to the data input, IH SkinPerm v2.04 model leads to the following results:
|
Instantaneous deposition |
Deposition over time End time observation 8 hr |
Total deposition (mg) or deposition rate (mg/cm²/hr |
1000 |
1 |
Fraction absorbed (%) |
2.94 |
0.367 |
Amount absorbed (mg) |
29.4 |
|
Lag time stratum corneum (min) |
7.28 |
|
Max. derm. abs. (mg/cm²/h) |
0.00184 |
Uptake across the epidermis is expected to be low (2.94%). This was confirmed in an acute dermal toxicity study resulting in an LD0 value of more than 2000 mg/kg bw (with no associated clinical signs). In addition, TBEC was not shown to be a skin sensitizer and is only slightly to moderately irritating for skin. The skin absorption rate is therefore limited and considered at 10% for risk assessment.
Inhalation
Based on the low vapour pressure of 4 10e-7 Pa, inhalation exposure is very unlikely. Nevertheless, if the substance reaches the lung, TBEC may be absorbed by micellular solubilisation. The low water solubility may enhance penetration to the lower respiratory tract.
Distribution
Once absorbed via the gastrointestinal tract it is likely that TBEC will be distributed systemically into cells due to its lipophilic properties and the intracellular concentration may be higher than extracellular concentration particularly in fatty tissues.
According to the pkCSM method (Pires et al., 2015) for predicting small-molecule pharmacokinetic properties, TBEC is expected to have a high steady state volume of distribution, a low fraction unbound to serum proteins, and to readily cross the blood-brain barrier and penetrate the CNS.
Metabolism
The metabolism of TBEC by cytP450 was evaluated by the Xenosite P450 Metabolism 1.0 software. XenoSite is able to predict the site of metabolism (SOM) of a molecule for cytP4501A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4 CYP isoforms (Pires et al., 2015). Xenosite computes a probability score varying between 0 and 1 (a high probability to be a SOM is characterized by a high score), which reflects both the confidence of the model that a particular atom is metabolised and the statistical likelihood that its prediction for that atom is correct, but they do not explicit model selectivity (which molecules are substrates of a given CYP enzyme). According to the cyt P450 isoforms and the substance isomers, TBEC is preferentially metabolized by cytP4502C9 on the hexyl radical.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 10
- Absorption rate - inhalation (%):
- 100
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.